STOK
Stoke Therapeutics, Inc.NASDAQHealthcare$32.74+2.34%ClosedMarket Cap: $1.94B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.43
P/S
10.52
EV/EBITDA
-131.08
DCF Value
$-51.03
FCF Yield
2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.9%
Operating Margin
-11.2%
Net Margin
-3.7%
ROE
-2.0%
ROA
-1.6%
ROIC
-5.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.4M | 24.8% | $-61.4M | $-57.9M | $-0.99 | — |
| FY 2025 | $184.4M | 100.0% | $-20.6M | $-6.9M | $-0.12 | — |
| Q3 2025 | $10.6M | 90.7% | $-43.1M | $-38.3M | $-0.65 | — |
| Q2 2025 | $13.8M | 100.0% | $-27.3M | $-23.5M | $-0.40 | — |
| Q1 2025 | $158.6M | 100.0% | $111.2M | $112.9M | $1.90 | — |
| Q4 2024 | $22.6M | 100.0% | $-13.7M | $-10.5M | $-0.18 | — |
| FY 2024 | $36.6M | 100.0% | $-101.4M | $-89.0M | $-1.65 | — |
| Q3 2024 | $4.9M | 100.0% | $-30.0M | $-26.4M | $-0.47 | — |
| Q2 2024 | $4.8M | 77.0% | $-29.3M | $-25.7M | $-0.46 | — |
| Q1 2024 | $4.2M | 73.6% | $-28.4M | $-26.4M | $-0.57 | — |
| Q4 2023 | $2.8M | 56.6% | $-29.6M | $-27.0M | $-0.60 | — |
| FY 2023 | $8.8M | 100.0% | $-114.8M | $-104.7M | $-2.38 | — |